Nyxoah SA
NYXHHealthcareNASDAQMedical Devices · Last scanned Sep 3, 2026
Scan Results
Daily timeframe1 of 4 indicators bearish as of Sep 2
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. At a $153.8M market cap, Nyxoah SA ranks as a micro-cap company within healthcare. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea.
Market Cap
$153.8M
Beta
0.95
P/E (TTM)
—
P/E (Fwd)
-1.55
EPS (TTM)
$-2.56
EPS (Fwd)
$-0.97
ROE
-122.7%
ROA
-36.9%
Cash
$97.8M
Total Debt
$60.0M
Free CF
-$46.1M
52W Change
-73.9%
Annual Financials
Cash vs Debt
Where NYXH stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NYXH finished 43.87% below its 150-day moving average ($2.69) and 52.96% below its 200-day moving average ($3.21). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NYXH overbought or oversold?
At the September 3, 2026 close, NYXH's RSI(14) was 41.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Nyxoah SA holds $97.8M in cash against $60.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$46.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -122.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $852K (2021) to $10.0M (2025), reflecting a 1076% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Nyxoah SA and its sector.